From the publishers of JADPRO
CAR T-Cell Therapy
Resource Center
Menu
Resources
Videos
Videos
Fast Facts
Quizzes
News & Literature Highlights
Case Studies
Advertisement
Test your knowledge of bloodless medicine management of a patient receiving CAR T-cell therapy
Last Updated: Wednesday, September 17, 2025
Loading...
Advertisement
News & Literature Highlights
Journal of Medical Cases
Cyclophosphamide for the treatment of refractory immune effector cell-associated neurotoxicity syndrome following CD19-targeted CAR T-cell therapy
Transplantation and Cellular Therapy
Financial toxicity in a phase I/II trial of LV20.19 CAR-T cell for B-cell malignancies a longitudinal, qualitative study
Experimental Biology and Medicine
Chimeric antigen receptor natural killer cell therapy for solid tumors: Mechanisms, clinical progress, and strategies to overcome the tumor microenvironment
Frontiers in Immunology
Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia
Blood
Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma
Mayo Clinic Proceedings. Innovations, Quality, & Outcomes
Operationalizing access for chimeric antigen receptor T cell therapies: A cross-functional perspective
World Journal of Oncology
Neurotoxicity of immunotherapy: Immune checkpoint inhibitor-related encephalitis vs. immune effector cell-associated neurotoxicity syndrome
Clinical and Translational Oncology
Emerging strategies to reduce the side effects of CAR-T cell therapy: Focusing on gene editing and nanotechnology
Transplantation and Cellular Therapy
Best practice considerations by the American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies
Blood Advances
CAR T-cell toxicities: From bedside to bench, how novel toxicities inform laboratory investigations
Advertisement
Case Studies
Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma
Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy
Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy
Fast Facts
Fast Facts #12: BCMA Targets
Advertisement
Quizzes
How much have you learned this year?
Test your knowledge of hemophagocytic lymphohistiocytosis following CAR T-cell therapy in a patient with multiple myeloma
Test your knowledge of bloodless medicine management of a patient receiving CAR T-cell therapy